Aldose reductase inhibitors and pharmaceutical compositions
AssigneeO.N.C.E.-(Organizacion Nacional De Cicgos)
InventorsTeresa Garcia de Quesada Fort, Jesús A De La Fuente Blanco, Ma Jesús Martin Lopez, Isabel Reymundo Cuesta
Life of this patent
Estimating the term…
Abstract
Medicaments for treating diabetic complications contain a compound of formula (A), wherein at least one Y or one Y′ is OH, and the remainder are selected from H, Hal, OH, OMe and NO2; X is O, S, keto or a direct link
Claims26
A compound according to the general formula (A)
- where X═O, Y2═Y2′═OH, Y6═Y6′═H, and Y3═Y3′═Y4═Y4′═Y5═Y5′═Br.
A compound according to the general formula (A)
- where X═O, Y2═Y2′═Y4═OH, Y6═Y6′═H, and Y3═Y3′═Y4′═Y5═Y5′═Br.
A compound according to the general formula (A)
- where X═O, Y2═Y2′═OH, Y6═Y6′═H, and Y3═Y3′═Y4═Y4′═Y5═Y5′═Cl.
A pharmaceutical composition for the treatment and/or prevention of diabetic complications comprising as an active ingredient a compound, or a pharmaceutically acceptable salt thereof, according to the general formula (A)
- where X═CO, Y2═Y2′═OH, Y4═Y4′═Y650 Y6′═H, and Y3═Y3′═Y5═Y5′═Br.
A pharmaceutical composition for the treatment and/or prevention of diabetic complications comprising as an active ingredient a compound, or a pharmaceutically acceptable salt thereof, according to the general formula (A)
- where X═ a single bond directly linking both substituted benzyl groups, Y4═Y4′═OH, and Y2═Y2′═Y3═Y3′═Y5═Y5′═Y6═Y6′═Br.
A pharmaceutical composition for the treatment and/or prevention of diabetic complications comprising as an active ingredient a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, according to the general formula (A)
- where X═ a single bond directly linking both substituted benzyl groups, Y4═Y4′═OH, and Y2═Y2′═Y3═Y3′═Y5═Y5′═Y6═Y6′═Cl.
A method of treating diabetic complications in mammals comprising the administration of a compound represented by the following general formula (A)
- or a pharmaceutically acceptable salt, hydrate or sovate therof, wherein at least one of Y or Y′ is OH;
- the others Y and Y′ are independently selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, and nitro;
- and
- X is selected from the group consisting of O, S, ketone, and a single bond directly linking both substituted benzyl groups.
A method of treating diabetic complications in mammals comprising the administration of a compound represented by the following general formula (A)
- or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein at least one of Y or Y′ is OH;
- at least one of Y or Y′ is a halogen;
- the others Y and Y′ are independently selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, and nitro;
- and
- X is selected from the group consisting O, S, ketone, and a single bond directly lining both substituted benzyl groups.
A method of treating diabetic complications in mammals comprising the administration of a compound represented by the following general formula (A)
- or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein at least one of Y or Y′ is OH;
- the others Y and Y′ are independently selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, and nitro;
- and
- X═O.
A method of treating diabetic complications in mammals comprising the administration of a compound represented by the following general formula (A)
- or a pharmaceutically acceptable salt, hydrate or solvate thereof wherein at least one of Y or Y′ is OH;
- the others Y and Y′ are independently selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, and nitro;
- and
- X is a single bond directly linking both substituted benzyl groups.
A method of treating diabetic complications in mammals comprising the administration of a compound represented by the following general formula (A)
- or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein at least one of Y or Y′ is OH;
- the others Y and Y′ are independently selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, and nitro;
- and
- X═S.
A method of preventing diabetic complications in mammals comprising the administration of a compound represented by the following general formula (A)
- or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein at least one of Y or Y′ is OH;
- the others Y and Y′ are independently selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, and nitro;
- and
- X is selected from the group consisting of O, S, ketone, and a single bond directly linking both substituted benzyl groups.
A method of preventing diabetic complications in mammals comprising the administration of a compound represented by the following general formula (A)
- or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein at least one of Y or Y′ is OH;
- at least one of Y or Y′ is a halogen;
- the others Y and Y′0 are independently selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, and nitro;
- and
- X is selected from the group consisting of O, S, ketone, and a single bond directly linking both substituted benzyl groups.
A method of preventing diabetic complications in mammals comprising the administration of a compound represented by the following general formula (A)
- or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein at least one of Y or Y′ is OH;
- the others Y and Y′ are independently selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, and nitro;
- and
- X═O.
A method of preventing diabetic complications in mammals comprising the administration of a compound represented by the following general formula (A)
- or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein at least one of Y or Y′ is OH;
- the others Y and Y′ are independently selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, and nitro;
- and
- X is a single bond directly linking both substituted benzyl groups.
A method of preventing diabetic complications in mammals comprising the administration of a compound represented by the following general formula (A)
- or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein at least one of Y or Y′ is OH;
- the others Y and Y′ are independently selected from the group consisting of hydrogen, halogen, hydroxy, methoxy, and nitro;
- and
- X═S.
Dependencies are inferred from the claim text.